Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo  >  ORIX Corporation    8591   JP3200450009


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

ORIX CORPORATION : ORIX Ventures Announces $10 Million Growth Capital Commitment to Talyst

share with twitter share with LinkedIn share with facebook
share via e-mail
11/07/2012 | 10:10am EST

Funding Supports Growth of Market Leader in Pharmacy Automation and Operations

ORIX Ventures announces the closing of a $10 million growth capital commitment to Talyst. The funding is structured to provide immediate growth capital to the company. Initial proceeds will be used to support Talyst's expansion into the long-term care and correctional markets, as well as its plans to achieve greater penetration in acute-care market.

Located in Seattle, Washington, Talyst is a leader in pharmacy automation providing enterprise-wide medication management across entire health systems. Its solutions offer greater inventory control, enhanced workflow efficiency and improved patient safety. Talyst was founded in 2002 to provide easy-to-use, automated medication management systems to acute-care hospital pharmacies.

The funding of Talyst underscores ORIX Ventures' intent to forge partnerships with fast-growing, later stage companies, as well as its particular interest in health care companies.

"We believe this funding from ORIX Ventures validates the market leadership and growth potential of Talyst," said CEO Carla Corkern. "Having a strong partner, such as ORIX Ventures, which can support the financial needs of Talyst throughout our expansion gives us a competitive edge by enabling us to respond quickly to marketplace opportunities."

David Orlandella, a Principal at ORIX Ventures, commented, "We are pleased to partner with Talyst's management team which has demonstrated an impressive ability to strategically scale the company and build a leading technology company in the pharmacy automation space."

About ORIX Ventures

ORIX Ventures provides customized financial solutions up to $50 million in capital per transaction to mid- and late-stage companies which have established customers and run-rate revenues of $10 million or greater. Since its inception in 2001, ORIX Ventures has invested in more than 100 growth companies throughout the U.S. and Canada. www.orixventures.com. ORIX USA is a Dallas, Texas-based financial services and investment firm with more than 1,400 employees and primary offices in Dallas, New York, Los Angeles, Columbus and Minneapolis. ORIX USA holds approximately $6 billion of assets and manages through various subsidiaries an additional $25 billion. www.orix.com. ORIX USA is a wholly owned subsidiary of ORIX Corporation, a Tokyo-based, publicly owned international financial services company with operations in 27 countries worldwide. ORIX Corporation is listed on the Tokyo (8591) and New York Stock Exchanges (IX).

Follow us on Twitter: @orixventures

About Talyst

Talyst is a leader in pharmacy automation and engineers the safer pharmacy. The company's solutions provide enterprise-wide medication management across entire health systems to offer greater inventory control, enhanced workflow efficiency, and improved patient safety. As of 2012, Talyst has installed automated systems in more than 600 integrated healthcare systems, acute-care hospitals, long-term care facilities, and correctional institutions. Talyst offers a powerful software platform with a suite of hardware components to meet specific needs of health care providers. Visit Talyst at www.talyst.com.

C. Pharr & Company for ORIX Ventures
Shelby Sabin Menczer, 214-763-6068

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
11/14ORIX : Main events scheduled for Saturday, Nov. 16
11/04ORIX : to Acquire U.S. Real Estate Loan Origination and Servicing Company, Hunt ..
11/04ORIX : USA to Expand Multifamily Banking Business with Acquisition of Hunt Real ..
10/28ORIX : Financial Highlights
10/28ORIX : Financial Results
10/28ORIX : Announcement Regarding Interim Dividend and Year-End Dividend Forecast fo..
10/28ORIX : Announcement Regarding Management Changes
10/28ORIX : Notice Regarding Repurchase and Cancellation of Own Shares
10/09ORIX : Craig Kahler Joins ORIX Capital Partners
09/27ORIX CORPORATION : Ex-dividend day for interim dividend
More news
Financials (JPY)
Sales 2020 2 288 B
EBIT 2020 336 B
Net income 2020 304 B
Debt 2020 6 565 B
Yield 2020 4,37%
P/E ratio 2020 7,19x
P/E ratio 2021 6,90x
EV / Sales2020 3,84x
EV / Sales2021 3,22x
Capitalization 2 225 B
Technical analysis trends ORIX CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Average target price 2 215,00  JPY
Last Close Price 1 738,50  JPY
Spread / Highest target 49,6%
Spread / Average Target 27,4%
Spread / Lowest Target -13,7%
EPS Revisions
Makoto Inoue Executive President, Group CEO & Director
Yoshihiko Miyauchi Senior Chairman
Shuji Irie Director, SVP, Head-Investment & Operations
Tamio Umaki Director, Chief Information Officer & GM-Personnel
Robert A. Feldman Independent Director
Sector and Competitors